Intravenous Weekly Topotecan In Subjects With Recurrent Or Persistent Endometrial Cancer

Endometrial Cancer Clinical Trial

Official title:

An Open-label, Phase II, Multicenter Study of Intravenous Weekly Topotecan in Subjects With Recurrent or Persistent Endometrial Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00267488
• Other study ID #: 100414
• Status: Completed
• Phase: Phase 2
• First received: December 20, 2005
• Last updated: June 28, 2012
• Start date: October 2005
• Est. completion date: December 2007

Study information

• Verified date: June 2012
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Health authority: Hungary: National Institute of PharmacyCanada: Canadian Institutes of Health ResearchUnited States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to find out if Hycamtin given weekly is safe and effective for treating your endometrial cancer.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 70
• Est. completion date: December 2007
• Est. primary completion date: December 2007
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• A subject will be eligible for inclusion in this study only if all of the following criteria are met:

• Subject has provided a written informed consent.

• Subject must be female and =18 years of age.

• Subjects' original endometrial carcinoma (any histologic type) must have had pathologic confirmation.

• Subject must have recurrent or persistent endometrial cancer.

• Subject must have at least one measurable lesion according to GOG-modified RECIST criteria.

• Measurable disease must be accurately measured in at least one dimension (longest dimension to be recorded). Each lesion must be = 20 mm when measured by conventional techniques, including palpation, plain X-ray, CT and MRI, or =10 mm when measured by spiral CT.

• Measurable disease found on chest X-ray must be confirmed with CT or MRI. Either CT or MRI must be used throughout the study to further evaluate these lesions.

• The same diagnostic method (CT, MRI, X-ray or physical exam) used to evaluate disease, must be used throughout the study to consistently evaluate lesions.

• Palpable tumor masses that cannot be evaluated by CT or MRI scan should be evaluated by ultrasound or confirmed by biopsy.

• Evaluable disease (measurable or non-measurable) may be in a field of prior radiation provided that at least six weeks have elapsed since receiving radiation and disease progression is clearly documented by radiographic study. It is preferential for the target lesion to be located outside an irradiated field.

• Non-measurable disease is defined as all other lesions, including small lesions (longest diameter <20 mm with conventional techniques or <10 mm with spiral CT scan).

• Subject has received one prior chemotherapy regimen (excluding all topoisomerase I inhibitors e.g., HYCAMTIN and irinotecan).

• Subject is allowed to have received, but is not required to have received, one additional prior non-cytotoxic regimen for management of recurrent or persistent disease according to the following definition: Non-cytotoxic (biologic or cytostatic) agents include, but are not limited to, monoclonal antibodies, cytokines, and small molecule inhibitors of signal transduction. UM2004/00031/00 CONFIDENTIAL HCT100414 20

• Subject is at least 21 days from prior chemotherapy and at least 30 days from prior non-cytotoxic therapy and is recovered from associated toxicities.

• Subject must not have received radiotherapy for at least seven days.

• Subject must be at least three weeks since last major surgery (a lesser period is acceptable if deemed in the best interest of the subject). Subject must have an ECOG Performance Status of 0 or 1 (refer to

• Appendix 4, ECOG Performance Status).

• Subject must have, at screening, a probable life expectancy of at least three months.

• Subject of childbearing potential must be practicing adequate contraception [e.g., oral contraceptives, diaphragm plus spermicide, or intrauterine device (IUD)] or show documented complete abstinence from intercourse for at least three months prior to study start. The same contraceptive method should be used throughout the study and continue for at least four weeks after the end of the study. A subject will be considered of childbearing potential if not surgically sterile or post-menopausal (i.e., documented absence of menses for one year prior to entry into the study).

14. Subject must have screening laboratory criteria as follows:

• Hemoglobin = 9.0 g/dL.

• Neutrophils = 1,500/mm³ [=1.5 x 10^9/L].

• Platelets = 100,000/mm³ [=100.0 x 10^9/L].

• Creatinine = upper limit of normal (ULN) or creatinine clearance (Clcreat) = 60mL/min.

• Creatinine clearance should be calculated using the Cockcroft-Gault formula:

Clcreat (mL/min) = (140-age [yr] x body wt [kg] x 0.85 72 x serum creatinine [mg/dL] OR Clcreat (mL/min) = 1.05 x (140-age [yr] x body wt [kg] serum creatinine [µmol/L]

• Serum bilirubin within normal limits.

• Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase < 2xULN if liver metastases are absent by abdominal CT or MRI or < 5xULN if liver metastases are present.

Exclusion Criteria:

A subject will not be eligible for inclusion in this study if any of the following criteria are met:

• Subject is pregnant or lactating.

• Subject has received more than one prior chemotherapy regimen. UM2004/00031/00 CONFIDENTIAL HCT100414 21

• Subject has concomitant or history of previous malignancies, with the exception of adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the subject has been disease-free for five years.

• Subject has active uncontrolled infection.

• Subject has brain metastases as documented by CT or MRI. Note: Asymptomatic subjects do not require CT or MRI to rule out brain metastases.

• Subject has received prior treatment with HYCAMTIN.

• Subject has a history of an allergic reaction to compounds chemically-related to HYCAMTIN or its constituents.

• Subject has received any investigational agent within 30 days or five half-lives (whichever is longer) prior to study entry.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Endometrial Cancer
• Endometrial Neoplasms
• Neoplasms, Endometrial

Intervention

Drug:
• topotecan

Locations

Country	Name	City	State
Canada	GSK Investigational Site	Calgary	Alberta
Canada	GSK Investigational Site	Montreal	Quebec
Canada	GSK Investigational Site	Ottawa	Ontario
Canada	GSK Investigational Site	Quebec
Hungary	GSK Investigational Site	Debrecen
United States	GSK Investigational Site	Atlanta	Georgia
United States	GSK Investigational Site	Chattanooga	Tennessee
United States	GSK Investigational Site	Chicago	Illinois
United States	GSK Investigational Site	Columbia	South Carolina
United States	GSK Investigational Site	Coral Gables	Florida
United States	GSK Investigational Site	Engelwood	Colorado
United States	GSK Investigational Site	Greenville	South Carolina
United States	GSK Investigational Site	Hinsdale	Illinois
United States	GSK Investigational Site	Knoxville	Tennessee
United States	GSK Investigational Site	LaJolla	California
United States	GSK Investigational Site	Lakeland	Florida
United States	GSK Investigational Site	Lincoln	Nebraska
United States	GSK Investigational Site	Los Angeles	California
United States	GSK Investigational Site	Miami	Florida
United States	GSK Investigational Site	Minneapolis	Minnesota
United States	GSK Investigational Site	New Orleans	Louisiana
United States	GSK Investigational Site	Newport Beach	California
United States	GSK Investigational Site	Orlando	Florida
United States	GSK Investigational Site	Seattle	Washington

Sponsors (1)

Lead Sponsor	Collaborator
GlaxoSmithKline

Countries where clinical trial is conducted

United States,  Canada,  Hungary, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Best Overall Response	Tumor response based on GOG (Gynecological Oncology Group) modified RECIST (Response Evaluation Criteria In Solid Tumors) criteria. A 4-point scale used specifying tumor response. Complete Response (CR): Disappearance of all target lesions; Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions; (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD; (PD): At least a 20% increase in the sum of the LD of target lesions	Week 0 to Week 98 when endpoints were met	No
Secondary	Time to Progression	Kaplan-Meier Estimate. Time to progression is defined as time from start of treatment until the first documented sign of disease progression or death due to progressive disease. Subjects who have not progressed or died at the time of analysis will be censored at the time of initiation of alternative anti-cancer therapy or time of last contact. Percentiles represent a set of points on a scale arrived at by dividing a group into parts in order of magnitude.	Week 0 to Week 19 when endpoints were met	No
Secondary	Overall Survival	Kaplan-Meier Estimate. Overall survival is defined as time from start of treatment until death due to any cause. Subjects who are alive at the time of analysis will be censored at the time of last contact.	Week 0 to Week 98	No
Secondary	Response Duration	The time from initial documented response to the first documented sign of progression or death due to progressive disease. Not calculated due to no Complete response and only 1 partial response.	Week 0 to week 98	No
Secondary	Time to Response	The time from start of treatment until the first documented response. Not calculated due to no Complete response and only 1 partial response.	Week 0 to week 98	No
Secondary	Safety and Tolerability as Summarized Through Adverse Event Reporting	AE = Adverse Event reported at a frequency of greater than or equal to 16%. SAE = Serious Adverse Events where all were reported at 0% frequency.	Week 0 to week 98	No